# SmartPA Criteria Proposal

| | |
|---|---|
| **Drug/Drug Class:** | Neuropathic Pain Agents PDL Edit |
| **First Implementation Date:** | May 29, 2013 |
| **Proposed Date:** | December 17, 2020 |
| **Prepared For:** | MO HealthNet |
| **Prepared By:** | MO HealthNet/Conduent |
| **Criteria Status:** | ☐Existing Criteria<br>☒Revision of Existing Criteria<br>☐New Criteria |

## Executive Summary

**Purpose:** The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

**Why Issue Selected:** Neuropathic pain results from damage or disease affecting the somatosensory system. It may be associated with abnormal sensations and pain produced by normally non-painful stimuli. Neuropathic pain may have continuous and/or episodic components. Common symptoms include burning or coldness, pins and needles sensations, numbness, and itching. This type of pain may result from disorders of the peripheral nervous system or the central nervous system and may be divided into peripheral or central neuropathic pain, or mixed (which includes both).

Total program savings for the PDL classes will be regularly reviewed.

**Program-Specific Information:**

| Preferred Agents | Non-Preferred Agents |
|---|---|
| • Gabapentin Caps/Tabs<br>• Lidocaine 5% Patch | • Gabapentin Soln<br>• Gralise®<br>• Horizant®<br>• Lidoderm®<br>• Neurontin®<br>• Qutenza®<br>• Ztlido™ |

**Type of Criteria:**
☒ **Increased risk of ADE**
☒ **Appropriate Indications**
☒ **Preferred Drug List**
☐ **Clinical Edit**

**Data Sources:**
☐ **Only Administrative Databases**
☒ **Databases + Prescriber-Supplied**

## Setting & Population

- Drug class for review: Neuropathic Pain Agents
- Age range: All appropriate MO HealthNet participants

## Approval Criteria

- Failure to achieve desired therapeutic outcomes with a trial on 1 or more preferred agents
  - Documented trial period for preferred agents **OR**
  - Documented ADE/ADR to preferred agents **AND**
- For Lidocaine 5% Topical Patch:
  - Approved for post-herpetic neuralgia
  - Participant is currently pregnant
- For Horizant: available for diagnosis of Restless Legs Syndrome
  - After therapeutic trial on ropinirole or pramipexole (trial defined as 30/180 days) **OR**
  - Documented ADE/ADR to these agents
- For Gabapentin solution: available for participants ≤ 10 years of age

## Denial Criteria

- Lack of adequate trial on preferred agents
- Therapy will be denied if all approval criteria are not met
- For Gabapentin: cumulative daily doses > 3600 mg
- **Claim exceed maximum dosing limitations for the following:**

| Drug Description | Generic Equivalent | Max unit/Day |
|---|---|---|
| GABAPENTIN 250 MG/CUP SOLUTION | GABAPENTIN | 60 ML |
| GABAPENTIN 300 MG/6ML SOLUTION | GABAPENTIN | 60 ML |
| GRALISE ER 300 MG TABLET | GABAPENTIN | 10 TABS |
| GRALISE ER 600 MG TABLET | GABAPENTIN | 5 TABS |
| HORIZANT ER 300 MG TABLET | GABAPENTIN ENACARBIL | 10 TABS |
| HORIZANT ER 600 MG TABLET | GABAPENTIN ENACARBIL | 5 TABS |
| LIDODERM 5% PATCH | LIDOCAINE | 3 PATCHES |
| NEURONTIN 100 MG CAPSULE | GABAPENTIN | 30 CAPS |
| NEURONTIN 250 MG/5 ML SOLN | GABAPENTIN | 60 ML |
| NEURONTIN 300 MG CAPSULE | GABAPENTIN | 10 CAPS |
| NEURONTIN 400 MG CAPSULE | GABAPENTIN | 8 CAPS |
| NEURONTIN 600 MG TABLET | GABAPENTIN | 5 TABS |
| NEURONTIN 800 MG TABLET | GABAPENTIN | 4 TABS |
| QUTENZA 8% KIT | CAPSAICIN/SKIN CLEANSER | 4 PATCHES |
| ZTLIDO 1.8% TOPICAL SYSTEM | LIDOCAINE | 3 PATCHES |

## Required Documentation

| | | | |
|---|---|---|---|
| Laboratory Results: | ☐ | Progress Notes: | ☐ |
| MedWatch Form: | ☐ | Other: | ☐ |

## Disposition of Edit

Denial: Exception Code “0160” (Preferred Drug List)
Rule Type: PDL

## Default Approval Period

1 year

## References


1. Evidence-Based Medicine and Fiscal Analysis: “Neuropathic Pain Agents – Therapeutic Class Review”, Conduent Business Services, L.L.C., Richmond, VA; October 2020.
2. Evidence-Based Medicine Analysis: “Neuropathic Pain”, UMKC-DIC; September 2020.
3. “Gabapentin Misuse, Abuse, and Diversion: A Systematic Review”. Havens, JR, Smith, RV, Walsh, SL. Addiction. 2016 July; 111(7): 1160–1174. doi:10.1111/add.13324.
4. Ohio Administrative Code, 4729 State Board of Pharmacy; Chapter 4729-37 Drug Database. Rule 4729-37-12: Dangerous Drug Monitoring. Rule effective December 2016. Ohio website accessed December 2017.
5. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2019.
6. USPDI, Micromedex; 2020.
7. Drug Facts and Comparisons On-line; 2020.